The case-control study analyzed the relationship between CYP2C19 polymorphism and the development of coronary artery disease (CAD) when dyslipidemia, diabetes, and chronic kidney disease are not present to reduce the impact of conventional coronary risk determinants. The gene discussed is CYP2C19; the disease is chronic kidney disease.